Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
March 28, 2023 09:00 ET
|
SciSparc Ltd
Upon the closing which occurred on March 22, 2023, the purchase price was adjusted from $2.5 million and increased to approximately $3 million. TEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE)...
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
March 10, 2023 16:15 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of...
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 09, 2023 07:30 ET
|
SciSparc Ltd
Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) --...
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 06, 2023 07:45 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
February 27, 2023 09:11 ET
|
SciSparc Ltd
The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
February 23, 2023 08:30 ET
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023 08:00 ET
|
SciSparc Ltd
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
February 17, 2023 08:00 ET
|
SciSparc Ltd
MitoCareX established its initial cloud-based computing infrastructure TEL AVIV, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023 08:30 ET
|
SciSparc Ltd
Clearmind’s applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s CannAmide™ and classical psychedelics ...
SciSparc Announces Corporate Restructuring plan
January 25, 2023 08:30 ET
|
SciSparc Ltd
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- SciSparc...